|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rivera C: Essentials of oral cancer. Int J
Clin Exp Pathol. 8:11884–11894. 2015.PubMed/NCBI
|
|
3
|
Guneri P and Epstein JB: Late stage
diagnosis of oral cancer: Components and possible solutions. Oral
Oncol. 50:1131–1136. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vokes EE: Induction chemotherapy for head
and neck cancer: Recent data. Oncologist. 15:3–7. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marcazzan S, Varoni EM, Blanco E, Lodi G
and Ferrari M: Nanomedicine, an emerging therapeutic strategy for
oral cancer therapy. Oral Oncol. 76:1–7. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Furness S, Glenny AM, Worthington HV,
Pavitt S, Oliver R, Clarkson JE, Macluskey M, Chan KK and Conway
DI: Interventions for the treatment of oral cavity and
oropharyngeal cancer: Chemotherapy. Cochrane Database Syst Rev.
13:CD0063862011.
|
|
7
|
Dokala A and Thakur SS: Extracellular
region of epidermal growth factor receptor: A potential target for
anti-EGFR drug discovery. Oncogene. 36:2337–2344. 2017. View Article : Google Scholar
|
|
8
|
Ogiso H, Ishitani R, Nureki O, Fukai S,
Yamanaka M, Kim JH, Saito K, Sakamoto A, Inoue M, Shirouzu M and
Yokoyama S: Crystal structure of the complex of human epidermal
growth factor and receptor extracellular domains. Cell.
110:775–787. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Downward J, Yarden Y, Mayes E, Scrace G,
Totty N, Stockwell P, Ullrich A, Schlessinger J and Waterfield MD:
Close similarity of epidermal growth factor receptor and v-erb-B
oncogene protein sequences. Nature. 307:521–527. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mendelsohn J: The epidermal growth factor
receptor as a target for cancer therapy. Endocr Relat Cancer.
8:3–9. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schultheis B, Reuter D, Ebert MP, Siveke
J, Kerkhoff A, Berdel WE, Hofheinz R, Behringer DM, Schmidt WE,
Goker E, et al: Gemcitabine combined with the monoclonal antibody
nimotuzumab is an active first-line regimen in KRAS wildtype
patients with locally advanced or metastatic pancreatic cancer: A
multicenter, randomized phase IIb study. Ann Oncol. 28:2429–2435.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cohen RB: Current challenges and clinical
investigations of epidermal growth factor receptor (EGFR)- and ErbB
family-targeted agents in the treatment of head and neck squamous
cell carcinoma (HNSCC). Cancer Treat Rev. 40:567–577. 2014.
View Article : Google Scholar
|
|
13
|
Ma H, Jin S, Yang W, Zhou G, Zhao M, Fang
S, Zhang Z and Hu J: Interferon-alpha enhances the antitumour
activity of EGFR-targeted therapies by upregulating RIG-I in head
and neck squamous cell carcinoma. Br J Cancer. 118:509–521. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Itai S, Yamada S, Kaneko MK, Chang YW,
Harada H and Kato Y: Establishment of EMab-134, a sensitive and
specific anti-epidermal growth factor receptor monoclonal antibody
for detecting squamous cell carcinoma cells of the oral cavity.
Monoclon Antib Immunodiagn Immunother. 36:272–281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kaneko MK, Yamada S, Itai S, Chang YW,
Nakamura T, Yanaka M and Kato Y: Elucidation of the critical
epitope of an anti-EGFR monoclonal antibody EMab-134. Biochem
Biophys Rep. 14:54–57. 2018.PubMed/NCBI
|
|
16
|
Itai S, Kaneko MK, Fujii Y, Yamada S,
Nakamura T, Yanaka M, Saidoh N, Handa S, Chang YW, Suzuki H, et al:
Development of EMab-51, a sensitive and specific anti-epidermal
growth factor receptor monoclonal antibody in flow cytometry,
western blot, and immunohistochemistry. Monoclon Antib Immunodiagn
Immunother. 36:214–219. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fujii Y, Kaneko M, Neyazaki M, Nogi T,
Kato Y and Takagi J: PA tag: A versatile protein tagging system
using a super high affinity antibody against a dodecapeptide
derived from human podoplanin. Protein Expr Purif. 95:240–247.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fujii Y, Kaneko MK, Ogasawara S, Yamada S,
Yanaka M, Nakamura T, Saidoh N, Yoshida K, Honma R and Kato Y:
Development of RAP tag, a novel tagging system for protein
detection and purification. Monoclon Antib Immunodiagn Immunother.
36:68–71. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fujii Y, Kaneko MK and Kato Y: MAP Tag: A
novel tagging system for protein purification and detection.
Monoclon Antib Immunodiagn Immunother. 35:293–299. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawada M, Inoue H, Kajikawa M, Sugiura M,
Sakamoto S, Urano S, Karasawa C, Usami I, Futakuchi M and Masuda T:
A novel monoclonal antibody targeting coxsackie virus and
adenovirus receptor inhibits tumor growth in vivo. Sci Rep.
7:404002017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Takei J, Kaneko MK, Ohishi T, Kawada M,
Harada H and Kato Y: A novel anti-EGFR monoclonal antibody
(EMab-17) exerts antitumor activity against oral squamous cell
carcinomas via antibody-dependent cellular cytotoxicity and
complement-dependent cytotoxicity. Oncol Lett. 19:2809–2816.
2020.PubMed/NCBI
|
|
22
|
Kato Y, Kunita A, Fukayama M, Abe S,
Nishioka Y, Uchida H, Tahara H, Yamada S, Yanaka M, Nakamura T, et
al: Antiglycopeptide mouse monoclonal antibody LpMab-21 exerts
antitumor activity against human podoplanin through
anti-body-dependent cellular cytotoxicity and complement-dependent
cytotoxicity. Monoclon Antib Immunodiagn Immunother. 36:20–24.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Takei J, Kaneko MK, Ohishi T, Kawada M,
Harada H and Kato Y: H2Mab-19, an anti-human epidermal growth
factor receptor 2 monoclonal antibody exerts antitumor activity in
mouse oral cancer xenografts. Exp Ther Med. 20:846–853. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mirza S, Hadi N, Pervaiz S, Khan SZ,
Mokeem SA, Abduljabbar T, Al-Hamoudi N and Vohra F: Expression of
HER-2/neu in oral squamous cell carcinoma. Asian Pac J Cancer Prev.
21:1465–1470. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Itai S, Ohishi T, Kaneko MK, Yamada S, Abe
S, Nakamura T, Yanaka M, Chang YW, Ohba SI and Nishioka Y:
Anti-podocalyxin antibody exerts antitumor effects via
antibody-dependent cellular cytotoxicity in mouse xenograft models
of oral squamous cell carcinoma. Oncotarget. 9:22480–22497. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kato Y and Kaneko MK: A cancer-specific
monoclonal antibody recognizes the aberrantly glycosylated
podoplanin. Sci Rep. 4:59242014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaneko MK, Nakamura T, Kunita A, Fukayama
M, Abe S, Nishioka Y, Yamada S, Yanaka M, Saidoh N, Yoshida K, et
al: ChLpMab-23: Cancer-specific human-mouse chimeric
anti-podoplanin antibody exhibits antitumor activity via
antibody-dependent cellular cytotoxicity. Monoclon Antib
Immunodiagn Immunother. 36:104–112. 2017. View Article : Google Scholar : PubMed/NCBI
|
